Nome, an AI-powered drug development startup, is automating the path from genetic diagnosis to clinical trials for ultra-rare diseases that traditional pharmaceutical companies largely ignore. The company currently oversees more than 10 genetic medicine programs and processes between 80 and 100 patient cases monthly, identifying potential treatment options in about 10 minutes—a process that once took dozens of hours.
Founder Stevie Ringel built Nome after his own experience navigating the rare-disease landscape. As a teenager, Ringel and his sister were both diagnosed with a type of retinal dystrophy caused by a mutation of the KIZ gene, a rare inherited genetic eye disorder that impacts less than 200 patients globally. There are no FDA-approved treatment options. That personal urgency drives Nome's model: serve patient groups too small to interest major pharma, but large enough to justify treatment development when the right tools exist.
Filling a Market Void
Jacalyn Lee, founder of The DAND Alliance, exemplifies the problem Nome targets. When her daughter Isla was diagnosed with DEAF1-Associated Neurodevelopmental Disorder—an ultra-rare genetic condition affecting about 200 patients worldwide—Lee received "this diagnosis, and little else. There was no roadmap, barely any research, no community that I was aware of at the time." She and four other mothers launched The DAND Alliance to fund treatment development but faced a critical gap: they didn't know how to spend their limited resources efficiently.
Nome provided exactly what they needed. The company delivered a 53-page report detailing next steps, from animal studies to trial design, at a price point and timeframe that surprised Lee. "They helped us figure out what the gaps are, what work streams we need to prioritize, and even potential researchers or vendors that we need to think about engaging with," Lee said. Ringel calls this approach a "white glove service" for developing treatments for underserved patient populations.
The business model reflects sound market logic. Patients upload genetic test results into Nome's system. The company's AI platform—which Ringel says is more accurate than readily available consumer models—searches for potential treatment options and provides a free detailed report. Of the roughly 5,000 cases Nome has examined to date, the company identified a programmable medicine or existing custom medical therapy that fits the known mutation about 25% of the time.
Nome makes revenue when customers hire it to design clinical trials or manage the full development process. Ringel describes this as acting "like a concierge drug developer working for you." The company uses AI to help design trials and manage logistics, with about 25% of Nome's work currently automated. Ringel believes that over the next one to two years, the company can automate 60% to 80% of the process.
The Cost Problem and Path Forward
Cost reduction is central to Nome's value proposition. A customized antisense oligonucleotide therapy (ASO) costs between $1.2 and $1.4 million. If Nome can bring that cost down by 50%, Ringel believes it could create a pathway for insurance coverage. He points to CAR-T cancer therapies as precedent: once considered too expensive for insurance to cover, they're now covered by most public and private plans.
Ringel acknowledges the skepticism. Some argue that Nome simply adds another layer of cost. His response: "I don't know how you can expect these families to move this process forward without someone playing quarterback." He contends that Nome ultimately saves patient groups both money and time by providing clear sequencing of what needs to happen next.
Nome works with more than 80 partners, including La Jolla Labs and Dyno Therapeutics, to access drug development expertise. This network approach allows a lean operation to punch above its weight in a traditionally capital-intensive industry.
Lee captures the broader opportunity: "I really believe that we are in this renaissance era of AI and gene therapy and patient advocacy." She references a comment from a nurse at her doctor's office: "The slow curve of progress is now a vertical line." For families facing devastating diagnoses with no known cure and minimal research, that acceleration matters enormously.
Why This Matters:
Nome represents a market-driven solution to a genuine gap that government programs and traditional pharma have failed to address. By automating analysis and trial design, the company demonstrates how technology can reduce the cost barriers that prevent treatment development for ultra-rare diseases. The startup's success hinges on its ability to lower development costs enough to attract insurance reimbursement—a shift that would validate the economics of personalized medicine for small patient populations. This model also illustrates why private enterprise, operating with patient-level urgency and minimal regulatory friction, often outpaces institutional solutions. If Nome succeeds in bringing costs down 50% and expanding insurance coverage, it could establish a template for serving other underserved medical markets, proving that profitability and compassionate care aren't mutually exclusive when market incentives align correctly.